Status of vaccine research and development for Campylobacter jejuni

Mark S. Riddle*, Patricia Guerry

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


Campylobacter jejuni is one of the leading causes of bacterial diarrhea worldwide and is associated with a number of sequelae, including Guillain-Barre Syndrome, reactive arthritis, irritable bowel syndrome and growth stunting/malnutrition. Vaccine development against C. jejuni is complicated by its antigenic diversity, a lack of small animal models, and a poor understanding of the bacterium's pathogenesis. Vaccine approaches have been limited to recombinant proteins, none of which have advanced beyond Phase I testing. Genomic analyses have revealed the presence of a polysaccharide capsule on C. jejuni. Given the success of capsule-conjugate vaccines for other mucosal pathogens of global importance, efforts to evaluate this established approach for C. jejuni are also being pursued. A prototypical capsule-conjugate vaccine has demonstrated efficacy against diarrheal disease in non-human primates and is currently in Phase I testing. In addition to proof of concept studies, more data on the global prevalence of capsular types, and a better understanding of the acute and chronic consequences of C. jejuni are needed to inform investments for a globally relevant vaccine.

Original languageEnglish
Pages (from-to)2903-2906
Number of pages4
Issue number26
StatePublished - 3 Jun 2016
Externally publishedYes


  • Campylobacter jejuni
  • Enteric vaccine development
  • Impact assessment
  • Travelers' diarrhea


Dive into the research topics of 'Status of vaccine research and development for Campylobacter jejuni'. Together they form a unique fingerprint.

Cite this